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Abstract
 
Dilated cardiomyopathy, resulting from myocarditis, is the most common cause of heart failure
in young patients. We here show that interleukin (IL)-1 receptor type 1–deficient (IL-1R1
 
 
 
/
 
 
 
)
mice are protected from development of autoimmune myocarditis after immunization with
 
 
 
-myosin-peptide(614–629). CD4
 
 
 
 T cells from immunized IL-1R1
 
 
 
/
 
 
 
 mice proliferated poorly
and failed to transfer disease after injection into naive severe combined immunodeficiency
(SCID) mice. In vitro stimulation experiments suggested that the function of IL-1R1
 
 
 
/
 
 
 
CD4
 
 
 
 T
cells was not intrinsically defect, but their activation by dendritic cells was impaired in IL-1R1
 
 
 
/
 
 
 
mice. Accordingly, production of tumor necrosis factor (TNF)-
 
 
 
, IL-1, IL-6, and IL-12p70
was reduced in dendritic cells lacking the IL-1 receptor type 1. In fact, injection of immature,
 
antigen-loaded IL-1R1
 
 
 
/
 
 
 
 but not IL-1R1
 
 
 
/
 
 
 
 dendritic cells into IL-1R1
 
 
 
/
 
 
 
 mice fully
restored disease susceptibility by rendering IL-1R1
 
 
 
/
 
 
 
 CD4
 
 
 
 T cells pathogenic. Thus, IL-1R1
triggering is required for efficient activation of dendritic cells, which is in turn a prerequisite for
induction of autoreactive CD4
 
 
 
 T cells and autoimmunity.
Key words: dendritic cells • interleukin 1 • interleukin 1 receptor type 1 • autoimmunity • 
myocarditis
 
Introduction
 
Idiopathic cardiomyopathy is the most common cause of
heart failure in young patients. A growing body of evi-
dence suggests that idiopathic cardiomyopathy may re-
sult from chronic myocarditis in predisposed individuals
(1–3). Experimental autoimmune myocarditis (EAM) is
a model for CD4
 
 
 
 T cell–mediated inflammatory heart
disease and can be induced in mice by immunization
with 
 
 
 
-myosin-heavy chain–derived peptides (4–6) to-
gether with CFA or CpG oligonucleotides. Proinflam-
matory cytokines like IL-12, IFN-
 
 
 
, and TNF-
 
 
 
 are
critically involved in the pathogenesis of autoimmune
myocarditis. Whereas TNF-
 
 
 
 (7) and IL-12 (8, 9) are
essential for the development of disease, IFN-
 
 
 
 protects
by a mechanism that probably involves nitric oxide (10).
IL-1 is a multifunctional player during host defense
and disease. It stimulates the acute phase response, the
secretion of matrix metalloproteinases, chemokines, and
other proinflammatory cytokines, acts as endogenous
pyrogen, and activates lymphocytes (11, 12). In the con-
text of autoimmunity, IL-1 promotes collagen-induced
arthritis in mice (13–15) and plays an important role in
the pathogenesis of rheumatoid arthritis in humans (16).
In fact, IL-1 antagonists are already used to treat patients
with rheumatoid arthritis. IL-1 is produced by a variety
of cell types including macrophages, B cells, T cells, and
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dendritic cells (DCs).
 
*
 
 Two forms of biologically active
IL-1 exist, IL-1
 
 
 
 and IL-1
 
 
 
, which exert similar activi-
ties through the IL-1R type 1 (IL-1R1; CD121a). The
IL-1R type 2 (IL-1R2; CD121b) is not considered to be
involved in the signal transduction, but acts as a “decoy”
receptor that can be shed from the cell surface and pre-
vents IL-1 binding to the IL-1R type 1 (17). In addi-
tion, an endogenous IL-1R antagonist (IL-1ra) has been
identified that binds to IL-1 receptors and blocks IL-1
binding and signaling (12).
The development of Coxsackie virus B3 (CVB3)-
induced myocarditis is associated with the infiltration of the
heart with inflammatory cells that secrete IL-1, and treat-
ment with recombinant IL-1 enhances CVB3 myocarditis
in partially resistant mice (18, 19). Furthermore, expression
of IL-1R antagonist in the mouse heart by plasmid DNA
decreases myocardial inflammation in CVB3 myocarditis
(20). However, the role of IL-1 and the IL-1R1 during in-
flammatory heart disease has not been established on the
genetic level. Our data provide the first in vivo evidence
that IL-1R1 triggering on DCs is critical for expansion of
autoreactive CD4
 
 
 
 T cells and subsequent induction of
autoimmune heart disease.
 
Materials and Methods
 
Mice and Immunization Procedures.
 
IL-1R1
 
 
 
/
 
 
 
 mutant mice
(provided by M. Labow, Hoffmann-La Roche, Nutley, NJ; refer-
ence 21) were backcrossed into BALB/c background for more
than eight generations in a specific pathogen free facility at the
Basel Institute for Immunology. Wild-type BALB/c mice were
purchased from Biological Research Laboratories Ltd. and SCID
(BALB/c) mice from Taconics. Female mice in the age of 8–10 wk
were immunized at days 0 and 7 with 50 
 
 
 
g of a murine specific
 
 
 
-myosin-heavy chain–derived peptide (myhc-
 
 
 
 614–629 [Ac-
SLKLMATLFSTYASAD-OH]) in a 1:1 emulsion with CFA (1
mg/ml; H37Ra; Difco) (5) All experiments were in accordance
with Swiss federal legislation and Canadian law and had been ap-
proved by the local authorities.
 
Histopathology and Immunohistochemistry.
 
21 d after the immu-
nization, hearts were removed and processed for hematoxylin-
eosin staining. Myocarditis was scored on a semiquantitative scale
using grades from 0 to 4 (0: no inflammatory infiltrates; 1: small
foci of inflammatory cells between myocytes; 2: larger foci of
 
 
 
100 inflammatory cells; 3: 
 
 
 
10% of a cross section involved; 4:
 
 
 
30% of a cross section involved). For immunohistochemistry,
OTC embedded frozen hearts were fixed in acetone and then pro-
cessed for antibody staining according to standard protocols. The
following antibodies were used: anti-MHC II (biotinylated; Sero-
tec; MCA46B), anti-CD45R (RA3–6B2), anti-CD3 (KT3–1.1),
anti-CD4 (YTS 191), anti-CD8 (YTS 169), anti-VCAM-1 mAb
(0.5 mg/ml, clone 429; BD Biosciences), anti-ICAM-1 (20 mg/
ml, clone 3E2; BD Biosciences); anti-Mac-1 (rat IgG, biotin-
ylated), anti-CD11c (2.5 mg/ml, clone HL3; BD Biosciences),
anti-Gr-1/Ly-6G (0.2 mg/ml, clone RB6–8C5; BD Biosciences).
 
Proliferation Assays.
 
CD4
 
 
 
 T cells were purified from drain-
ing lymph nodes of immunized mice using magnetic beads
(CD4
 
 
 
 T cell isolation kit; Miltenyi Biotech) and cultured for 72 h
together with irradiated (2,000 rad) syngenic splenocytes, with
or without 10 
 
 
 
g/ml of myhc
 
 
 
 614–634 in serum-free AIM-V/
myhc(614–629) (GIBCO BRL) medium. Proliferation was as-
sessed by measuring [
 
3
 
H]methyl-thymidine incorporation. IFN-
 
 
 
,
IL-2, IL-10, and IL-4 levels in supernatants were measured us-
ing commercially available ELISA kits (Quantikine; R&D Sys-
tems) after 40 h of culture in the presence of myhc-
 
 
 
. For in vitro
stimulation assays of primary CD4
 
 
 
 T cells, naive CD62L-posi-
tive CD4
 
 
 
 T cells were isolated from lymph nodes by depletion/
positive selection with magnetic beads (CD4
 
 
 
 isolation kit,
CD62L microbeads, MACS; Miltenyi Biotech). 10
 
5
 
 CD4
 
 
 
CD62L
 
 
 
 cells were then stimulated by 5 
 
 
 
g/ml soluble anti-
CD3
 
 
 
, 5 
 
 
 
g/ml anti-CD3
 
  
 
and 1 
 
 
 
g/ml anti-CD28, 50 ng/ml
PMA and 500 ng/ml Ionomycin, or with 1 
 
 
 
g/ml Concanavalin
A together with 0.25 
 
 
 
 10
 
5
 
 irradiated (1,500 rad) purified non-
stimulated DCs. Proliferative responses were assessed after 24 or
48 h in serum free AIM-V (GIBCO BRL) medium at 37
 
 
 
C/5%
CO
 
2
 
 by measuring [
 
3
 
H]methyl-thymidine incorporation.
 
Generation of DCs, Cytokine Measurements, and FACS
 
®
 
 Analy-
sis.
 
DCs were generated as described (22). CD11c positive cells
were further enriched by positive selection using magnetic beads
(MACS; Miltenyi Biotech). Generally, FACS
 
®
 
 analysis for CD11c
expression and microscopic assessment of the typical cell morphol-
ogy revealed over 80% of DCs. For cytokine measurements, DCs
were plated at 10
 
6
 
/ml in 24 well plates and incubated for 24 h with
various stimuli including 5 
 
 
 
g/ml anti-CD40, 1 
 
 
 
g/ml LPS, 5 
 
 
 
g/
ml anti-CD40, and 1 
 
 
 
g/ml LPS, 500 U/ml TNF-
 
 
 
, or 10 ng/ml
of IL-1
 
 
 
. TNF-
 
 
 
, IL-1
 
 
 
, IL-12p70, and IL-6 were measured us-
ing Quantikine ELISA kits (R&D Systems). For FACS
 
®
 
 analysis,
DC preparations were preincubated for 30 min at 4
 
 
 
 with Fc-block
(BD Biosciences) and 1% rat serum in BD Biosciences staining
buffer before incubation with the appropriate fluorochrome la-
beled antibodies from BD Biosciences.
 
Adoptive Transfer of In Vitro–restimulated CD4
 
 
 
 T Cells and DC
Treatment Protocol.
 
Spleens from donor mice were removed
21 d after the first immunization. CD4
 
 
 
 T cells were enriched using
magnetic beads (MACS; Miltenyi Biotech) and cultured for 48 h
on antigen pulsed and irradiated (1,500 rad) syngenic DCs. 5 
 
 
 
10
 
6
 
 CD4
 
 
 
 T cells per mouse (
 
 
 
98% CD4
 
 
 
 cells) were intraperi-
toneally injected in to SCID (IL-1R1
 
 
 
/
 
 
 
) mice. Recipients were
killed 10 d after transfer, and myocarditis severity was assessed.
For in vivo reconstitution with antigen-pulsed DCs, we gener-
ated immature DCs by adding 20 ng/ml of IL-10 to the culture me-
dium. 1 d prior to harvesting, cells were pulsed overnight with the
myhc-
 
 
 
 peptide at 10 
 
 
 
g/ml. After enrichment of CD11c-positive
 
*
 
Abbreviations used in this paper:
 
 BM-DC, bone marrow–derived dendritic
cell; DC, dendritic cell; IL-1R1, IL-1 receptor type 1; myhc-a, a-myo-
sin peptide(614-629); TLR, Toll-like receptor.
 
Table I.
 
Myocarditis Prevalence and Severity in IL-1R1
 
 
 
/
 
 
 
 and 
IL-1R1
 
 
 
/
 
 
 
 Mice
 
Prevalence
Severity grade
(at day 21)
Mice Treatment Day 21 Median range
IL-1R1
 
 
 
/
 
 
 
None 9/9
 
a
 
2 (1–4)
IL-1R1
 
 
 
/
 
 
 
None 0/11
 
a
 
0
 
a
 
P 
 
  
 
0.0001 for IL-1RI
 
 
 
/
 
 
 
 vs. IL-1RI / ; Fisher’s exact test.T
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cells using magnetic beads, 2   105 CD11c MHC class IIlow  DCs
per mouse were intraperitoneally injected 6 h before immunization
with myhc-  and CFA on days 0 and 7.
Results
IL-1R1 /  Mice Are Protected from Autoimmune Myocardi-
tis. To investigate the role of IL-1R1–mediated effects on
the pathogenesis of murine autoimmune myocarditis, ho-
mozygous female IL-1R1 /  mice and IL-1R1 /  con-
trols on a BALB/c background were immunized with a
peptide derived from mouse  -myosin (myhc- ). Disease
prevalence and severity were assessed by histology and im-
munohistochemistry 21 d after the first immunization. IL-
1R1 /  mice developed severe cardiac inflammation. In-
flammatory infiltrates mainly consisted of mononuclear
cells including macrophages, CD4  T cells, and CD8  T
cells, as well as some granulocytes and eosinophils (Fig. 1).
In contrast, inflammatory infiltrates were absent in immu-
nized IL-1R1 /  mice (Table I). This effect was not dose
dependent, because disease prevalence and severity did not
increase in IL-1R1 /  and IL-1R1 /  mice with higher
antigen doses (data not depicted).
Reduced Activation of Autoreactive CD4  T Cells. Au-
toimmune myocarditis is a CD4  T cell mediated disease
(6). To test the function of myosin-specific CD4  T cells
in immunized IL-1R1 /  mice, we purified CD4  T cells
from draining lymph nodes and restimulated them with the
myhc-  peptide on irradiated IL-1R1 /  antigen-present-
Figure 1. IL-1R1 /  mice are protected from autoimmune myocarditis and rendered susceptible by transfer of IL-1R1 /  DCs. (A and B) Mice were
immunized with myhc-  and hearts were evaluated at day 21. Inflammatory infiltrates are present in hearts of IL-1R1 /  (A) but not IL-1R1 /  mice (B).
(C and D) IL-1R1 /  mice were reconstituted with immature myhc- –pulsed bone marrow DCs derived from naive IL-1R1 /  mice (wt-DC→ ko-mice)
(C) or IL-1R1 /  mice (ko-DC→ ko-mice) (D) before immunization with myhc- . Myocarditis is seen in wt-DC → ko-mice (C) but not in ko-DC →
ko-mice (D). (E and F) CD4  T cells purified at day 21 after immunization of mice described in C and D were restimulated in vitro with myhc-  for 48 h
before transfer into naive IL-1R1 /  SCID (BALB/c) recipients. At day 10 after adoptive transfer, unimmunized SCID mice develop myocarditis by transfer
of IL-1R1 /  CD4  T cells isolated from wt-DC → ko-mice (E) but not from ko-DC → ko-mice (F). 480  original magnification.
 
Table II. Myocarditis Prevalence after Adoptive Transfer of
In Vitro Antigen-restimulated CD4  T Cells in SCID (Ad)
Mutant Mice
Prevalence in
SCID recipients
CD4  
donor mice Immunization of donor mice
Day 10
after transfer
IL-1R1 /  myhc-  and CFA 6/6 group A
IL-1R1 /   myhc-  and CFA 0/5 group B
IL-1R1 /   myhc- /CFA/IL-1RI /  DC 5/6 group C
IL-1R1 /   myhc- /CFA/IL-1RI /  DC 0/6 group D
P   0.022 group A vs. group B, P   0.0152 group C vs. group D,
P   0.0152 group B vs. group C; Fisher’s exact test.
ing cells in vitro. Compared with controls, self-specific
CD4  T cells from IL-1R1 /  mice proliferated poorly
(Fig. 2 A), and produced little IL-2 and IFN- , whereas
IL-4 and IL-10 production appeared to be intact (Fig. 2 B).
To further investigate the function of autoimmune
CD4  T cells in vivo, we performed adoptive transfer ex-
periments. CD4  T cells from immunized IL-1R1 / 
mice and IL-1R1 /  controls were isolated at day 21, were
expanded in vitro in the presence of specific antigen, and
were injected into SCID mice. As shown previously (4),T
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transfer of autoreactive CD4  T cells from IL-1R1 / 
BALB/c mice resulted in myocarditis in SCID recipients
(Table II). In contrast, IL-1R1 / CD4  T cells did not in-
duce any disease after adoptive transfer into SCID mice
(Table II). These data clearly confirm that autoimmune
myocarditis can be induced by autoreactive CD4  T cells
and that the IL-1R1 is essential for their optimal activation
in vivo. Given the impaired in vivo CD4  T cell response
in IL-1R1 /  mice, we asked whether the activation of
CD4  T cells intrinsically requires IL-1R1 signaling. To
this end, we isolated naive CD62L CD4  T cells from
healthy donor mice and triggered them for 24 or 48 h with
Figure 2. Reduced CD4  T cell responses in immunized
IL-1R1 /  mice. Groups of mice were immunized with
myhc-  and CD4  T cells were isolated 21 d later and re-
stimulated with 10  g/ml myhc-  in vitro. (A) Proliferation
was measured by [3H]-thymidine incorporation after 48 h.
Values indicate means (  SD) of three individual mice. *P  
0.036 for antigen restimulated IL-1R1 /  vs. IL-1R1 / 
CD4  T cells (analysis of variance [ANOVA] and unpaired t
test). (B) Cytokines in the supernatant were measured by
ELISA after 40 h of restimulation with specific myhc-  anti-
gen. Values indicate means (  SD) of 4–5 individual mice.
*P   0.0037 for IL-2, and P   0.0001 for IFN-  production
of IL-1R1 /  vs. IL-1R1 /  CD4  T cells. P values were
calculated using ANOVA and the unpaired t test. (C) CD4 
CD62L  T cells were purified from naive mice by MACS
and stimulated with (i) soluble anti-CD3  (5  g/ml), (ii)
anti-CD3  (5  g/ml) and anti-CD28 (1  g/ml), (iii) PMA
(50 ng/ml) and Ionomycin (500 ng/ml), or (iv) with Con-
canavalin A (1  g/ml) together with 0.25   105 unstimulated
DCs. Proliferation was measured after 48 h of culture with
the indicated stimuli. *P   0.0001 for both, IL-1R1 /  and
IL-1R1 /  DCs. P values were calculated using ANOVA
and the unpaired t test. Values are expressed as mean ( SD)
of five different mice. (D) Con A induced proliferation of
IL-1R / CD4  T cells on irradiated splenocytes (APC) in
the presence of increasing numbers of either IL-1R1 / 
(black bars) or IL-1R1 /  (yellow bars) DCs. One out of
four representative experiments is shown. Values are ex-
pressed as mean ( SD) of four culture wells.T
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various stimuli. As shown in Fig. 2 C, naive IL-1R1 / 
and IL-1R1 / CD4  T cells showed comparable prolifer-
ation upon stimulation with anti-CD3 , anti-CD3 /anti-
CD28, PMA/Ionomycin, or Concanavalin A presented by
wild-type DCs. Interestingly, both IL-1R1 /  and IL-
1R1 / CD4  T cells showed impaired proliferation upon
Con A stimulation in the presence of DCs derived from
IL-1R1 /  mice. However, IL-1R1 /  DCs do not sup-
press CD4  T cell proliferation upon Con A in the pres-
ence of irradiated splenocytes. This is illustrated in Fig. 2
D, where increasing numbers of IL-1R1 /  DCs enhance
IL-1R1 / CD4  T cell proliferation, albeit to a much
lesser extent than IL-1R1 /  DCs. Taken together, these
data suggest that reduced CD4  T cell activation in IL-
1R1 /  mice immunized with self-peptide results from a
defect at the level of DCs rather than from an intrinsic de-
fect of CD4  T cells in the absence of IL-1R1.
Impaired Production of Proinflammatory Cytokines by IL-
1R /  DCs after In Vitro Stimulation. To test whether the
absence of the IL-1R1 on DCs affected their immune stim-
Figure 3. Up-regulation of costimulatory molecules
and production of proinflammatory cytokines in IL-
1R1 /  and IL-1R1 /  DCs. (A) FACS® profiles repre-
senting only minimal differences in the expression of
costimulatory molecules on IL-1R1 /  (blue) and IL-
1R1 /  (red) DCs before and after stimulation with
LPS/anti-CD40 for 8 h. Histogramms were gated on
CD11c MHC class II  live cells (ICAM, B7.1, B7.2) or
CD11c  live cells. (B) Mature BM-DCs were stimulated
for 24 h as indicated. IL-12p70, TNF- , IL-6, and IL-1 
were measured by ELISA. Data for IL-1R1 /  DCs
(black bars) and IL-1R1 /  DCs (yellow bars) are ex-
pressed as mean ( SD) from quadruplicate culture
wells. Differences between IL-1R1 /  and IL-1R1 / 
DCs were highly significant for all cytokines following
LPS, or LPS/anti-CD40 stimulation. IL-1R1 /  DCs
also produced significantly reduced levels of TNF- , IL-
1 , and IL-6 after stimulation with anti-CD40 alone,
significantly reduced levels of IL-6 and IL-1  after
TNF-  stimulation, and significantly reduced TNF- 
levels after IL-1  stimulation. (All P values 0.0001 or
 0.0001, following ANOVA and unpaired t test). The
data are representative for several independent experi-
ments with similar results.T
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ulatory capacity, we measured the expression of costimula-
tory molecules and the production of proinflammatory cy-
tokines in response to various stimuli. Surface expression of
MHC class II, CD40, ICAM-1, CD80, and CD86 differed
only minimally on bone marrow–derived DCs (BM-DCs)
from IL-1R1 /  and IL-1R1 /  mice before and after (8
and 24 h) stimulation with either LPS, anti-CD40 mAb, or
LPS/anti-CD40 mAb (Fig. 3 A). Furthermore, we did not
observe any differences in the proportions of living and ap-
optotic CD11c  BM-DCs in cell cultures after 24 h (not
shown). Production of inflammatory cytokines including
IL-6, TNF- , IL-1 , and IL-12p70 by wild-type BM-DCs
were considerably induced only after stimulation of Toll-
like receptor (TLR)4 with LPS but not by stimulation with
either anti-CD40, IL-1 , or TNF- . Interestingly, stimula-
tion of both TLR4 and CD40 further augmented produc-
tion of IL-12p70 but not IL-6 and TNF- . As illustrated in
Fig. 3 B, production of IL-6, TNF- , IL-1  and, in partic-
ular, IL-12p70 was largely impaired in IL-1R1 /  DCs
upon stimulation with LPS or LPS/anti-CD40. Preliminary
data from our laboratory indicate that stimulation of TLR9
with CpG also resulted in impaired IL-12p70 production
by IL-1R1 /  DCs (not shown). Coadministration of an
anti–IL-1  blocking antibody to DC cultures during stimu-
lation inhibited production of proinflammatory cytokines
by IL-1R1 /  DCs similar than the IL-1R1 genetic defect
(Fig. 4). Taken together our results suggest that triggering
of the IL-1R1 is required for optimal activation of DCs to
secrete proinflammatory cytokines including IL-12, which
promote CD4  activation.
Injection of IL-1R1 /  Antigen Pulsed DCs Restores Myo-
carditis Susceptibility of IL-1R1 /  Mice. We next asked
whether susceptibility to myocarditis could be restored in
IL-1R1 /  mice by reconstitution with IL-1R1 /  DCs.
We grew immature BM-DCs in the presence of IL-10 to
prevent activation and possibly tolerance induction (23)
and pulsed them with myhc-  before injection in IL-
1R1 /  mice. Subsequently, mice were immunized with
myhc- /CFA. Intriguingly, disease susceptibility was com-
pletely restored in IL-1R1 / mice receiving IL-1R1 / 
DCs but not in those receiving IL-1R1 /  DCs (Fig. 1,
and Table III), and histology of the hearts of DC reconsti-
tuted IL-1R1 /  mice was not different from diseased IL-
1R1 /  controls (Fig. 1). Importantly, disease severity in
IL-1R1 /  mice was not significantly reduced after injec-
tion of immature IL-1R1 /  DCs excluding a relevant
tolerogenic role for IL-1R1 /  immature DCs in our ex-
perimental setting. Efficient in vivo priming of autoreactive
T cells in IL-1R1 /  mice reconstituted with immature
IL-1R1 /  DCs was finally confirmed by the fact that
CD4  T cells isolated from these mice transferred disease
upon injection into SCID (IL-1R1 / ) recipients (Fig. 1,
and Table II). In conclusion, our data provide strong evi-
dence that triggering of IL-1R1 on DCs is critical for in-
duction of a pathogenic autoreactive CD4  T cell response
and development of autoimmune heart disease.
Discussion
Our data demonstrate an essential role of the IL-1 path-
way in the development of autoimmune inflammatory
Figure 4. Neutralization of IL-1  reduces production of proinflamma-
tory cytokines by BM-DCs. Mature bone marrow–derived IL-1R1 / 
and IL-1R1 /  DCs were cultured for 24 h in the presence or absence of
an anti–IL-1  antibody. Cytokines were detected by ELISA. Data for
CD40/LPS stimulated DCs (black bars) and nonstimulated DCs (yellow
bars) are expressed as mean ( SD) from triplicate culture wells.
Table III. Myocarditis Prevalence and Severity in Immunized
IL-1R1 /  and IL-1R1 /  Mice after Supplementation with 
Immature, myhc- –loaded DCs
Mice
Dendritic
cells
Prevalence
Severity grade
(at day 21)
Day 21 Median range
IL-1R1 /  IL-1R1 /  0/5a 0
IL-1R1 /  IL-1R1 /  5/6a 3 (0–4)
IL-1R1 /  IL-1R1 /  6/6b 4 (3–4)c
IL-1R1 /  IL-1R1 /  4/5b 2 (0–3)c
aP   0.0152.
bP   0.4545, Fisher’s exact test.
cP   0.081, Mann-Whitney U test.T
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heart disease. Mice lacking the IL-1R1 were protected
from myocarditis and showed impaired priming of heart
myosin specific CD4  T cells, which resulted from defec-
tive activation of DCs. To our knowledge, this is the first
publication showing that inefficient DC activation prevents
induction of autoimmune disease.
Members of the IL-1R/Toll-like receptor (TLR) super-
family including IL-1R1 and IL-18R commonly induce
the signaling cascade MyD88 → IRAK1/IRAK2 →
TRAF6 leading to the activation of the transcription factor
nuclear factor (NF)- B, p38 mitogen-activated protein ki-
nase (MAPK), and Jun-N terminal kinase. The NF- B
pathway appears to play an important role in the develop-
ment of autoimmune diseases and inactivation ameliorates
EAE (24) and collagen-induced arthritis (25, 26), which has
been implicated with the inhibition of Th1 responses. NF-
 B may promote the production of IFN-  by T cells di-
rectly by interaction with a functional NF- B site in the
IFN-  promoter or by activation of p38 MAPK through
regulation of GADD45  in response to IL-18 (27). In our
studies, we also observed reduced IFN-  production by
antigen-specific CD4  T cells of immunized IL-1R1 / 
mice. However, this does not provide a direct explanation
for the protection from heart inflammation, because
IFN-  /  mice develop exacerbated myocarditis (8–10).
On the other hand, IL-1 and NF- B activation has also
been associated with the development of Th2 responses
(28–30), but we found that IL-4 and IL-10 production was
unaffected after restimulation of CD4  T cells from immu-
nized IL-1R1 /  mice excluding immune deviation and
the induction of IL-10  regulatory T cells. Furthermore,
Th2 cells do not play a crucial role in autoimmune myo-
carditis, although they can modulate the disease (8). Re-
gardless whether IL-1 and NF- B regulate IFN-  or IL-4
production in CD4  T cells, our data clearly show that
pathogenic CD4  T cells in the IL-1R1 /  mice were
fully activated and induced disease when they encountered
IL-1R1 /  DCs presenting the antigen. A normal Th1 and
Th2 subset polarization was also observed when naive
IL-1R1 / CD4  specific for OVA323–339 were stimulated
with cognate antigen in the presence of wild-type DCs
(unpublished data).
Transfer of immature BM-DCs from wild-type mice
completely restored disease in IL-1R1 /  mice suggesting
that DCs lacking the IL-1R1 are incapable to prime CD4 
T cells and induce autoimmunity. It is conceivable that IL-1
acts on DCs by stimulating their capacity to up-regulate
CD40L and OX40 on CD4  T cells (31). DCs might re-
quire IL-1R1 triggering for proper development, migra-
tion, antigen processing/presentation, or/and for optimal
activation. In preliminary experiments, some of these possi-
bilities were addressed. We purified CD11c  DCs from
lymph nodes and spleen of naive mice and analyzed them
by flow cytometry. The frequency of CD8  and CD8 
DCs and the expression levels of MHC class II, CD86, and
CD40 were comparable in IL-1R1 /  and IL-1R1 / 
mice indicating that DC development was not grossly af-
fected (not shown). Our experiments using BM-DCs sug-
gest that IL-1R1 triggering is required for production of a
panel of pro-inflammatory cytokines including IL-12p70,
IL-1, IL-6 and TNF- , which are all known to be targets
of NF- B (32, 33). Reduced production of these cytokines
was also observed when BM-DCs from wild-type mice
were stimulated in the presence of neutralizing anti-IL-1 
mAb (Fig. 4). This finding is in keeping with results ob-
tained with human DC subsets (34).
Interestingly, IL-1R1 /  DCs seem not to have a relevant
defect to mature upon stimulation, as the up-regulation of
CD80, CD86, and ICAM-1, the latter also activated by NF-
 B, was almost comparable to IL-1R1 /  DCs.
Nevertheless, we cannot exclude that other DC func-
tions such as their migratory capacity is reduced in the ab-
sence of IL-1R1 (35, 36). Regardless, the impaired pro-
duction of TNF- , IL-6, and IL-12 itself may explain
disease resistance of IL-1R1 / mice, because each of them
is indispensable for the induction of autoimmune myo-
carditis (7, 8, 37).
The phenotype of in vitro–activated IL-1R1 /  DCs
appears somewhat reminiscent to the TNF- –induced
semimature DCs described by Menges et al. (23), which
showed impaired IL-12p70 production but normal up-reg-
ulation of costimulatory molecules upon stimulation. These
semimature DCs were tolerogenic in a model of CD4  T
cell–mediated autoimmune disease. Despite the fact that
injection of immature IL-1R1 /  DCs did not prevent dis-
ease in immunized IL-1R1 /  mice, we cannot exclude a
potential tolerogenic role for IL-1R /  DCs because our
experimental setting is different from the published toler-
ance induction protocol (23).
N. Rose and coworkers had shown that IL-1 treatment
renders otherwise resistant mouse strains susceptible to viral
myocarditis and suggested an important role for IL-1 and
TNF-  in up-regulation of adhesion molecules on endo-
thelial cells (18). ICAM-1 expression has been shown to be
critical for the recruitment of inflammatory cells in Cox-
sackie B3–induced myocarditis (38). Our data do not rule
out a role for IL-1R1 signaling in endothelia activation or
target organ homing of antigen-specific T cells. The fact
that reconstitution with IL-1R1 /  DCs alone is sufficient
in restoring myocarditis susceptibility and normal expres-
sion of endothelia activation markers in reconstituted IL-
1R1 / mice, suggest that IL-1R1–mediated mechanisms
are either not decisive in mediating the access of autoreac-
tive CD4  T cells to the heart or may be compensated by
redundant pathways.
Recently, it has been shown that structural proteins of
several microorganisms potentially affecting the human
heart show homology to the pathogenic  -myosin peptide
in BALB/c mice and to the human  -myosin (39). Our
findings contribute to the understanding of how DC acti-
vation may be initially modulated by microbial products in
the absence of T cells and in the presence of innate signals.
Indeed, the initial activation of DCs phagocyting debris
and microbes containing potential self-peptide homo-
logues might determine whether a pathogenic autoreac-
tive response evolves or not. In this context, IL-1R1 sig-T
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naling may play an important role bridging innate and
adaptive immunity.
Taken together, our data show that IL-1R1 signaling in-
duces autoimmunity by critically enhancing the capacity of
antigen-presenting DCs to prime autoreactive T cells.
Given the availability of clinically effective drugs targeting
IL-1, our findings open new therapeutic perspectives in the
treatment of inflammatory heart disease. Meanwhile, our
data are a major step forward in understanding the mecha-
nisms underlying autoimmunity and cardiac inflammation.
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